These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31487383)

  • 1. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
    Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
    Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
    Joly P; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Vermeulin T; Benichou J; Musette P;
    Lancet; 2017 May; 389(10083):2031-2040. PubMed ID: 28342637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: A Review in Pemphigus Vulgaris.
    Frampton JE
    Am J Clin Dermatol; 2020 Feb; 21(1):149-156. PubMed ID: 31838645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
    Tedbirt B; Maho-Vaillant M; Houivet E; Mignard C; Golinski ML; Calbo S; Prost-Squarcioni C; Labeille B; Picard-Dahan C; Chaby G; Richard MA; Tancrede-Bohin E; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Musette P; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
    JAMA Dermatol; 2024 Mar; 160(3):290-296. PubMed ID: 38265821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial.
    van Beek N; Eming R; Reuss A; Zillikens D; Sárdy M; Günther C; Kiritsi D; Benoit S; Beissert S; Gläser R; Gollnick H; Horváth ON; Pfeiffer C; Röcken M; Schauer F; Schreml S; Steinbrink K; Zink A; Schade-Brittinger C; Hertl M; Schmidt E
    Br J Dermatol; 2024 Apr; 190(5):657-667. PubMed ID: 38133541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first-line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial.
    Hébert V; Vermeulin T; Tanguy L; Tedbirt B; Mignard C; Bénichou J; Joly P
    Br J Dermatol; 2020 Jul; 183(1):121-127. PubMed ID: 31657454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Pemphigus Vulgaris and Foliaceus with Adjuvant Rituximab Compared to Immunosuppression Alone: Real-Life Experience.
    Snast I; Spitzer L; Hodak E; Levi A; Mimouni D; Leshem YA
    Dermatology; 2021; 237(2):179-184. PubMed ID: 32756069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
    Mignard C; Maho-Vaillant M; Golinski ML; Balayé P; Prost-Squarcioni C; Houivet E; Calbo SB; Labeille B; Picard-Dahan C; Konstantinou MP; Chaby G; Richard MA; Bouaziz JD; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
    JAMA Dermatol; 2020 May; 156(5):545-552. PubMed ID: 32186656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: A retrospective analysis.
    Agarwal A; Hall RP; Bañez LL; Cardones AR
    PLoS One; 2018; 13(9):e0198074. PubMed ID: 30252855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study.
    Zhou X; Zhan T; Xu X; Lan T; Hu H; Zhou Y; Xia D; Wang J; Wang Y; Xiao Y; Li W
    J Dermatolog Treat; 2024 Dec; 35(1):2302071. PubMed ID: 38247364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.
    Baum S; Gilboa S; Greenberger S; Pavlotsky F; Trau H; Barzilai A
    J Dermatolog Treat; 2013 Dec; 24(6):427-30. PubMed ID: 23521340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey.
    Uzun S; Bilgiç Temel A; Akman Karakaş A; Ergün E; Özkesici B; Eskiocak AH; Erat A; Uğurlu N; Nazlım B; Koç S; Bozkurt S; Dicle Ö; Alpsoy E; Yılmaz E
    Int J Dermatol; 2016 Dec; 55(12):1362-1368. PubMed ID: 27653507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
    Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
    J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil as a first-line steroid-sparing agent in the treatment of pemphigus vulgaris.
    Vyas N; Patel NS; Cohen GF
    J Drugs Dermatol; 2013 Feb; 12(2):210-6. PubMed ID: 23377396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single cycle of rituximab for the treatment of severe pemphigus.
    Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
    N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
    Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
    J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months.
    Balighi K; Daneshpazhooh M; Akbari Z; Tavakolpour S; Azimi P; Azizpour A
    J Dermatolog Treat; 2019 Jun; 30(4):346-349. PubMed ID: 30081690
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term prognosis of pemphigus in Korea: retrospective analysis of 199 patients.
    Kim MR; Kim HC; Kim SC
    Dermatology; 2011; 223(2):182-8. PubMed ID: 22025028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
    Sami N; Qureshi A; Ruocco E; Ahmed AR
    Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.